The IBTA’s monthly e-News has been released and has emailed to all subscribers. Emailed to 5,000 people around the globe, including clinicians, patients, researchers and others, it gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
This month’s highlights
You can read the IBTA e-News July/August 2024 edition in full online here.
Some highlights from this month’s round-up:
- Servier has announced that the U.S. Food and Drug Administration (FDA) has approved Voranigo (vorasidenib), an IDH1 and IDH2 inhibitor, for the treatment of adult and paediatric patients with Grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation
- A new phase 1/2 clinical trial led by NCI-CONNECT is testing whether a chemotherapy called PLX038 can treat adults with primary central nervous system (CNS) cancers that have extra copies of MYC and MYCN genes (called MYC and MYCN “amplified” tumours).
- According to a paper published in The Journal of Neurosurgery, a medical research team from Osaka Metropolitan University in Japan has developed a minimally invasive surgical technique called a “purely endoscopic subtemporal keyhole ATPA” for operating on tumours located in the base of the skull, one of the most challenging sites for neurosurgery.
- According to a study published in Cell, a team of researchers has identified and located a population of stem-like cells that appears to initiate and maintain the growth of Group 3 medulloblastoma (Gr3-MB) in the developing brain. Study author Dr Michael D Taylor, professor of paediatrics, haematology-oncology and neurosurgery at Baylor and Texas Children’s Hospital, said: “We believe that as GR3-MB develops, it retains characteristics present in embryonic development, resulting in rapid tumour growth. Our goal was to identify embryonic cells that would give rise to tumours, as well as their location and factors that drive their growth.”
- Ipsen and Day One Biopharmaceuticals have announced a new global partnership outside the United States for tovorafenib, an oral, once-weekly, type II RAF inhibitor for paediatric low grade glioma (pLGG), the most common form of childhood brain cancer, and any future indications developed by Day One. Tovorafenib was granted Orphan Drug Designation and received US FDA approval in April 2024 as a monotherapy treatment for patients six months and older with relapsed or refractory pLGG harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation.
To see an archive of existing e-News issues, click here.
Sign up to receive the e-News every month by registering here.
